Pathological overproduction: the bad side of adenosine
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Adenosine is an endogenous ubiquitous purine nucleoside, which is increased by hypoxia, ischaemia and tissue damage and mediates a number of physiopathological effects by interacting with four GPCRs, identified as A 1, A 2A, A 2B and A 3. Physiological and acutely increased adenosine is mostly associated with beneficial effects that include vasodilatation and a decrease in inflammation. In contrast, chronic overproduction of adenosine occurs in important pathological states, where long‐lasting increases in the nucleoside levels are responsible for the bad side of adenosine associated with chronic inflammation, fibrosis and organ damage. In this review, we describe and critically discuss the pathological overproduction of adenosine and analyse when, where and how adenosine exerts its detrimental effects throughout the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · cited 1×
“…conditions Inflammation is a hallmark of important diseases such as cardiovascular, metabolic, intestinal and pulmonary Bad sides of adenosine BJP British Journal of Pharmacology (2017) 174 1945–1960 1949 disorders (Hotamisligil, 2006; Libby et al., 2011; Barnes, 2016; Karin and Clevers, 2016).”
BackgroundPurinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778 · cited 1×
“Interestingly, the well-known epidemiological consideration that caffeine protects against PD has been confirmed in an animal model of PD and attributed to A2A receptor antagonism (Ross et al., 2000; Ascherio et al., 2001, 2004; Chen et al., 2001; Yu et al., 2008; Xu et al., 2016).”
BackgroundReparative inflammation takes charge of tissue regeneration
Karin, M., & Clevers, H. (2016) · Nature · doi:10.1038/nature17039 · Cited by 767
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“Interestingly, the well-known epidemiological consideration that caffeine protects against PD has been confirmed in an animal model of PD and attributed to A2A receptor antagonism (Ross et al., 2000; Ascherio et al., 2001, 2004; Chen et al., 2001; Yu et al., 2008; Xu et al., 2016).”
BackgroundAdenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419 · cited 1×
“Nevertheless, evidence in favour of A2A receptor activation as a strategy for HD treatment has also been reported (Gomes et al., 2011; Martire et al., 2013; Tyebji et al., 2015).”
BackgroundA Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385 · cited 3×
“Adenosine plays a role in promoting cancer development by evoking immunosuppressive effects and directly affecting the growth, metastasis and angiogenesis of tumour cells (Antonioli et al., 2014; Allard et al., 2016; Di Virgilio and Adinolfi, 2016; Ohta, 2016) (Figure 6).”
BackgroundThe neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Kaster, M. P., Machado, N. J., Silva, H. B., Nunes, A., Ardais, A. P., Santana, M., Baqi, Y., Müller, C. E., Rodrigues, A. L. S., Porciúncula, L. O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423088112 · Cited by 312 · cited 1×
“Furthermore, caffeine or selective A2A receptor antagonists reversed the performance deficits in reserpine-treated rats and prevented mood and memory dysfunctions induced by chronic stress (Batalha et al., 2013; Kaster et al., 2015; Minor and Hanff, 2015).”
Background
Cited by
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Self-citationReview of the neurological benefits of phytocannabinoids
Maroon, J., & Bost, J. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_45_18 · Cited by 203
“Increased adenosine is associated with neuroprotection and decreased inflammation after brain trauma.[7,16] CBD is also known to exert vascular effects, producing vasodilation as well as hypotension that may hold promise as protectant against cerebrovascular damage associated with stroke.”
BackgroundPurinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
“…neuroinflammatory responses, excitotoxicity, oxidative stress and cell death, especially via A2A and P2X7 receptors activity, respectively (Cunha, 2016; Borea et al., 2017; Faas et al., 2017; Faria et al., 2017; He et al., 2017; Lu et al., 2017; Miras-Portugal et al., 2017; Vuorimaa et al.,…”
BackgroundPasquini, S., Contri, C., Cappello, M., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030895 · Cited by 29
Self-citation
Metadata
- Authors
- Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-03-31
- Volume
- 174
- Issue
- 13
- Pages
- 1945-1960
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2591914678
- Cited by
- 118
- References
- 18
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.